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Purpose: Nigeria has adopted quinine as the drug of first choice in the treatment of severe malaria and 
artemether as an alternative therapy. The purpose of this study was to ascertain whether artemether is a 
comparable alternative to quinine in the management of severe malaria in Nigerian children.  
Methods: We conducted a randomized prospective study comparing quinine and artemether therapies 
in 90 Nigerian children with severe malaria.  
Results: Mortality was lower in quinine group (13.0 %) than artemether (15.9 %), Odds Ratio (OR) = 
0.446 (95 % Confidence Interval (CI), 0.124 to 1.603, p = 0.249 ). The parasitaemia clearance on day 3 
by quinine and artemether was 96.8 and 99.0 % (p = 0.422), respectively, while on day 14 it was 100 % 
for both medicines. Fever clearance by quinine and artemether was 87.7 and 90 % (p = 0.753), 
respectively, on day 3 but it increased to 100 and 96.42 % (p = 0.072), respectively, on day 14. For the 
quinine group, 71.74 % of the patients spent less than one week in the hospital versus 61.76 % for the 
artemether group (p = 0.829, OR = 0.883, 95 %CI = 0.284 to 2.742).  
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INTRODUCTION 
 
Each year, worldwide, there are about 300 - 
500 million clinical cases of malaria and an 
estimated 1.1 - 2.7 million deaths as result of 
severe malaria [1]. Over 90 % of deaths 
occur in children below 5 years of age, mainly 
from cerebral malaria in children 2 - 5 years 
and anaemia in children 0.5 – 2 years [2]. 
Neurological sequelae persisting for more 
than 6 months occur in more than 2 % of the 
survivors, and they include ataxia, 
hemiplegia, speech disorders, behavioural 
disorders, epilepsy and blindness. Severe 
malaria with anaemia has case fatality rate 
higher than 13 % [3]. 
  
Of increasing concern is the declining 
efficacy of quinine in parts of southeast Asia 
[4], a trend that could prove disastrous if it 
spreads to Africa, where most deaths from 
malaria occur. Thus, there is an urgent need 
to identify new forms of therapy for severe 
malaria that are economical and practical 
alternatives to quinine and, ideally, improve 
the clinical outcome of severe malaria. 
Among potential alternatives to quinine, the 
artemisinin (qinghaosu) derivatives have 
attracted special interest because of the 
rapidity with which they reduce Plasmodium 
falciparum parasitaemia [5]. Nigeria has 
adopted parenteral quinine as the drug of first 
choice in the treatment of severe malaria and 
artemether as an alternative therapy [6]. 
Thus, in this study, we have compared the 
effectiveness of quinine and artemether in 






This study was conducted in Federal Medical 
Centre, Birnin Kudu, Jigawa State of Nigeria. 
This is a heavily malaria-infested area, as a 
result of its ever growing population and the 
presence of many ponds, pools and rivers 
which serve as sources of water for domestic 
and agricultural purposes. Malaria is 
characterised by a stable, perennial, 
transmission in all parts of the state. The 
transmission of malaria is higher in the wet 
(rainy) season than in the dry season in the 
state, with a peak at the former from May to 
late September. The centre was chosen 
because it is the only tertiary health facility, 
the highest referral centre and also has better 
medical services and documentation than 




The children who met the inclusion criteria 
were enrolled in the study and randomly 
assigned to receive either quinine or 
artemether therapy. Patients were assigned 
to receive quininie if the last digit of their 
hospital identification number was odd and to 
receive artemether if the last digit of their 
hospital identification number was even or 
zero. This study was conducted from July 6 
to October 24, 2007. This period was chosen 
because malaria transmission and hospital 
admission are usually high due to heavy 
rainfall during this period. 
 
Children between 6 months and 12 years of 
age presenting with fever (> 37.5 °C ) and P. 
falciparum infection cases, with one or more 
general danger signs of severe or 
complicated malaria were included in the 
study based on the following definition of 
severe malaria [7]:  
 
In a patient with P. falciparum asexual 
parasitaemia and no other obvious cause of 
their symptoms, the presence of one or more 
of the following clinical or laboratory features 
classifies the patient as suffering from severe 
malaria: 
 
Clinical manifestation: Prostration, impaired 
consciousness, respiratory distress (acidotic 
breathing), multiple convulsions, circulatory 
collapse, pulmonary oedema (radiological), 
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abnormal bleeding, jaundice and 
Haemoglobinuria. 
 
Laboratory test: Severe anaemia, 
hypoglycaemia, acidosis, renal impairment, 
hyperlactataemia and hyperparasitaemia.  
 
Excluded were patients with serious 
concomitant illness, e.g., sick cell anaemia, 
HIV, tuberculosis and other chronic diseases; 
patients without any manifestations of severe 
malaria; and patients with severe malnutrition 
and known hypersensitivity to one of the 
study drugs. In addition, children below 6 
months and those above 12 years were not 
included. 
 
Structured data collection form was used for 
collection of demographic characteristics, 
clinical and treatment variables. Laboratory 
report form was used for recording laboratory 
findings. The forms were filled by the 
appropriate personnel serving in the hospital. 
Forty-six children (28 females and 18 males)  
were included in the quinine treatment group 
and they received quinine 20 mg salt/kg body 
weight (bw) on admission (i.v. infusion or 
divided i.m. injection, as a loading dose), then 
10 mg/kg bw every 8 h; the infusion rate did 
not exceed 5 mg salt/kg bw per hour. Forty-
four children (24 females and 20 males) were 
included in the artemether group and they 
received artemether 3.2 mg/kg bw i.m. given 
on admission, as a loading dose and then 1.6 
mg/kg bw per day for 2 days. Quinimax
®
 
injection manufactured by Sanofi and 
Paluther
® 
injection manufactured by May and 
Baker were used in this study. A quantitative 
parasite count of asexual forms was 
performed (using the parasite/white blood cell 
count) at day 0, day 3 and day 14. The 
parasite clearance was taken as adequate 
clinical and parasitological response (ACPR) 
at days 3 and 14. 
 
Their body temperatures were taken two 
times daily during the admission. Fever 
clearance was taken as body temperature ≤ 
37.5 
o
C after treatment had commenced. 
Pediatric Coma Scale (PCS) developed by 
Simpson and Reilly [8,9] was used to assess 
the consciousness of the patients at days 0, 
1, 2 and 3. Normal aggregate score adjusted 
for age according to Simpson and Reilly was: 
0 - 6 months: 9; > 6 - 12 months: 11; > 1 - 2 
years: 12; > 2 - 5 years: 13; > 5 years: 14. 
Any patient who had aggregate score below 
his specified normal age adjusted score was 
taken to be comatose. Mortality was 
estimated by the number of patients that died 
in the hospital. Hospital bed-days were 
calculated by the actual number of days each 
patient spent in the hospital. The patients 





Data analysis was performed using SPSS for 
Windows 13.0 (SPSS Inc., Chicago, IL). We 
used χ2 tests to compare categorical data 
(Fisher exact for groups smaller than n = 5). 
Continuous data were tested for normality 
(test for skewness, Shapira – Wilkoxon test 
for normality). Normally distributed data were 
analysed with independent samples T-tests, 
and non-normally distributed data with Mann-
Whitney U test. A two-tailed significance level 
of 0.05 was used. Multivariate regression 
analysis was performed to determine whether 
baseline characteristics were associated with 
the outcome of treatment. Age, weight, sex, 
severity, number of co-morbidities, initial 
parasite count, and initial temperature were 
entered into the model as linear variable or 
classified categories. Intention-to-treat 




Necessary clearance was obtained from the 
University of Nigeria Teaching Hospital 
ethical committee and written consent was 
also obtained from the children’s care takers. 
Moreover, confidentiality was maintained 
during data collection and processing, and 
the procedures did not endanger or have 
adverse effects on the patients. 
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RESULTS 
 
A total of 90 children were included in the 
study, 46 were treated with quinine while 44 
were treated with artemether. Two patients 
absconded in each group, representing 4.35 
and 4.55 % for quinine and artemether, 
respectively. Six of 46 children treated with 
quinine died in the hospital (13.04 %), 
compared with 7 of 44 patients treated with 
artemether (15.90 %).  Thirty-one of 38 
children discharged in the quinine group 
came back for follow-up (81.58 %) on day 14, 
compared with 30 of 35 children discharged 
in the artemether group (85.70 %). 
Multivariate regression analysis showed that 
none of the baseline characteristics 
influenced the outcomes significantly; 
independent of these, the treatment group 
was the primary determinant of the study 
outcomes (Table 1). The clinical features on 







































1.80 1.57 0.08 -1.73 0.43 -3.85 2.31 0.35 
c
Haemoglobin 
day 14 (g/dl) 
 
8.87 























-0.16 0.17 -0.77 -3.22 0.45 -0.88 2.80 -1.736 
 
a 
R = 0.23,  R
2
 = 0.053    Adjusted R
2
 = 0.051 
b
 R = 0.42,  R
2
 = 0.18      Adjusted R
2
 = 0.18 
c
 R = 0.38  R
2
 = 0.14       Adjusted R
2
 = 0.14 
d
 R = 0.46  R
2
 = 0.21      Adjusted R
2
 = 0.22 
e
 R = 0.51  R
2
 = 0.26       Adjusted R
2
 = 0.26       
f
 R = 0.31  R
2
 = 0.096      Adjusted R
2
 = 0.097                                           
g
 R = 0.45  R
2
 = 0.20       Adjusted R
2
 = 0.20 
*
 P- value > 0.05 
Body Temperature on day 0 (Body Temp day 0), Parasitaemia Density on day 0 (Para day 0), Consciousness 
status on day 0 (CNS day 0) 
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*Age (years) 3.2±1.7 3.8±1.3 
¶
 Sex, F/M (%F) 28/18(60.9) 24/20(54.54) 
*Mean weight (kg) 14.74±8.42 12.48±5.9  
¶
 Co-morbidities (%)   
      Gastroenteritis 17(36.96) 20(45.46) 
     Acute upper respiratory tract                           
      Infections 
12(26.01) 8(23.53) 
    Acute lower respiratory tract 
     Infections 
2(4.35) 4(9.09) 
    None    15(32.61) 12(35.29) 
¶ 
Comatose patients (%) 10(21.74) 7(15.90) 
¶




* Body temperature (
o
C) 38.27±0.51 38.36±0.42 
¥
 Geometric mean of parasitaemia (per µL 







 Frequency of patients (percentage); *Mean (±SD)  
¥ 
Geometric mean (range) 
 
 
Six of 46 children treated with quinine died in 
the hospital (13.04 %), compared with 7 of 44 
patients treated with artemether (15.90 %); 
RR= 0.446 (95 %CI, 0.124 to 1.603, p = 
0.249). Most of the deaths occurred within 
the first 3 days of admission in both treatment 
groups; 61.54, 76.92 and 84.62 % of these 
deaths occurred by days 1, 2 and 3, 
respectively. Mortality was calculated based 
on the patients that died in the hospital. 
 
Parasitaemia clearance of quinine on day 3 
was (96.8 %), compared with 99.0 % 
clearance by artemether (p = 0.422) by 
Mann-Whitney test); however, parasitaemia 
clearance (ACPR) was (100 %) in both drug 
groups on day 14. The fever clearance of 
children treated with quinine and artemether 
were 87.7 and 90.0 % (p = 0.753)                                                                       
, respectively at day 3, and 100 and 96.42 % 
(p = 0.072) in quinine and artemether, 
respectively, at day 14. 
 
Although quinine showed greater effect on 
coma recovery on day 3, there was no 
significant difference when the treatment 
groups were compared (p = 0.763) (Table 3). 
The probability of recovering from coma in 
the artemether and quinine groups, 
respectively, was 0.43 and 0.50 within day 1; 
0.71 and 0.80 within day 2, and 0.86 and 
0.90 within day 3. The proportion of patients 
that spent less than one week in the hospital 
in quinine and artemether treatment groups 
were 71.74 and 61.76 %, respectively (RR = 




Quinine showed higher mortality prevention 
than artemether; the point estimate was 
consistent with quinine being associated with 
a massive 55% reduction in mortality risk vis 
a vis artemether. It had been widely 
anticipated that a more rapid reduction of 
parasitaemia would bring about a 
corresponding reduction in mortality. The 
odds ratios had wide confidence limits and 
one cannot exclude the possibility that 
artemether would reduce mortality if its use 
were widespread. Several smaller trials in 
southeast Asia suggested that treatment with 
artemisinin derivatives might reduce mortality 
by 50 % [5]. Our finding suggests that the 
speed of parasite clearance may be a 
relatively unimportant determinant of survival.  
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Table 3: Results of outcome parameters  
 






¥Mortality 20.59 13.04  0.124 to 1.603 0.446 
¥Coma Recovery  15.90 21.74  0.065 to 9.015 0.763 
ð Parasitaemia clearance 
on day 3 
(259±81)99 (320±89)96.8 0.422   
ð Parasitaemia clearance   
on day 14 
(122±23)100 (163±32)100 0.672   
¶
Fever clearance on day 
3 (temperature ≤ 37.5 
o
C) 





Fever clearance on day 
14 (temperature ≤ 37.5 
o
C) 




¶Hospital  bed-days  
(≤7 days) 
(7.1±1.6)62 (7.03±1.76)71  0.284 to 2.742 0.883 




 Percentage of patients;, 
ð
 (Geometrical mean±SE) percentage 
 
In this case, part of the explanation may be 
that artemether preferentially accelerates the 
clearance of younger parasites, which are 
those seen in the circulation, over more 
mature parasites, which are located deep in 
the vasculature and mediate organ damage 
[10].  
 
The study revealed a shorter coma recovery 
time in the quinine group. There has been 
concern that artemether may be neurotoxic at 
high doses. This has been observed in 
studies in animals, but it is yet to be 
demonstrated in human beings [11]. The 
tendency toward a longer time to recovery 
from coma in the artemether group could 
possibly be due to such an effect.  
 
This study showed that parasitaemia 
clearance on day 3 was higher in artemether 
group than in the quinine group. Although 
ACPR was 100 % at day 14 in both groups, 
none of them completely eliminate the 
parasites. This study supports findings that 
both artemether and quinine lack the ability to 
prevent malaria re-infection [12,13]. 
 
Fever clearance was higher in the artemether 
group than in the quinine group on day 3 and 
day14 but the difference was not significant. 
This effect may be attributed to the relatively 
higher parasitaemia clearance exhibited by 
artemether as well as increasingly quinine 
resistance. The proportion of patients that 
spent less than one week in the hospital were 
higher in the quinine group than in the 
artemether group but the difference was not 
statistically significant. The greater parasi-
taemia clearance found in artemether did not 
reflect in the number of days spent in the 
hospital.  
 
The World Health Organization currently 
recommends that artemisinin derivatives 
alone should not be used as first-line 
treatment in Africa, in order to delay the 
development of resistance to this valuable 
class of antimalarial compounds [14]. 
 
Limitations of the study 
 
The following limitations were inherent in the 
study and the results were interpreted in this 
light. Fourteen days were not enough for a 
study of this kind because the true failure 
rates may have been higher. It has been 
estimated that 28-day assessments 
underestimate the true failure by about 20 % 
for drugs with intermediate elimination half-
life, such as lumefantrine and sulfadoxine-
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pyremethamine (3 – 6 days half-life), and as 
much as 40 % for drugs with a longer 
elimination half-life, such as 
desethylamodiaquine [15,16]. The sample 
size was small. Loss to follow-up was 18.4 
and 14.3% in quinine and artemether 
respectively but losses were equally 
distributed between the two treatments. 
Some baseline characteristics were based on 




This study has shown that quinine and 
artemether are comparable alternatives. 
Although quinine prevented mortality to a 
greater extent than artemether, other non-
fatal measures of disease activity showed 
some similarity between the treatments. 
Using artemether as an alternative to quinine 
does not only provide alternative 
chemotherapy against severe malaria but 
should also help to preserve the other against 
ever-emerging antimalarial drug resistance 
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